Compare LPSN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPSN | ATNM |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 31.7M |
| IPO Year | 2000 | 2013 |
| Metric | LPSN | ATNM |
|---|---|---|
| Price | $2.83 | $1.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 227.5K | 166.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $249,838,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.58 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.39 | $0.74 |
| 52 Week High | $7.54 | $1.81 |
| Indicator | LPSN | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 70.97 |
| Support Level | $2.44 | $0.94 |
| Resistance Level | $2.88 | $1.27 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 85.60 | 91.56 |
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.